🇺🇸 FDA
Pipeline program

cytarabine

I 245213

Phase 2 small_molecule terminated

Quick answer

cytarabine for Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome is a Phase 2 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Teva Pharma GmbH
Indication
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials